Literature DB >> 26731013

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site.

M Pavel1, D O'Toole, F Costa, J Capdevila, D Gross, R Kianmanesh, E Krenning, U Knigge, R Salazar, U-F Pape, K Öberg.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26731013     DOI： 10.1159/000443167

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN： 0028-3835            Impact factor:   4.914


× No keyword cloud information.
  249 in total

Review 1.  Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.

Authors:  Marco Gallo; Pasqualino Malandrino; Giuseppe Fanciulli; Francesca Rota; Antongiulio Faggiano; Annamaria Colao
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-12       Impact factor: 4.553

2.  177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study.

Authors:  Giovanni Paganelli; Maddalena Sansovini; Silvia Nicolini; Ilaria Grassi; Toni Ibrahim; Elena Amadori; Valentina Di Iorio; Manuela Monti; Emanuela Scarpi; Alberto Bongiovanni; Mattia Altini; Luca Urso; Corrado Cittanti; Federica Matteucci; Stefano Severi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-29       Impact factor: 9.236

Review 3.  Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2016-09-23       Impact factor: 3.889

Review 4.  Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.

Authors:  David L Chan; Diego Ferone; Manuela Albertelli; Nick Pavlakis; Eva Segelov; Simron Singh
Journal:  Endocrine       Date:  2017-07-19       Impact factor: 3.633

5.  Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient.

Authors:  Manuel Weber; Lukas Kessler; Benedikt Schaarschmidt; Wolfgang Peter Fendler; Harald Lahner; Gerald Antoch; Lale Umutlu; Ken Herrmann; Christoph Rischpler
Journal:  BMC Cancer       Date:  2020-04-16       Impact factor: 4.430

6.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889

Review 7.  Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors.

Authors:  Hiroshi Imaoka; Mitsuhito Sasaki; Hideaki Takahashi; Yusuke Hashimoto; Izumi Ohno; Shuichi Mitsunaga; Kazuo Watanabe; Kumiko Umemoto; Gen Kimura; Yuko Suzuki; Motoyasu Kan; Masafumi Ikeda
Journal:  Oncologist       Date:  2018-08-02

8.  Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis.

Authors:  Bryson W Katona; Giorgio A Roccaro; Michael C Soulen; Yu-Xiao Yang; Bonita J Bennett; Brian P Riff; Rebecca A Glynn; Damian Wild; Guillaume P Nicolas; Daniel A Pryma; Ursina R Teitelbaum; David C Metz
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

Review 9.  Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.

Authors:  Peter E Goretzki; Martina T Mogl; Aycan Akca; Johann Pratschke
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 10.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.